×
About 1,028 results

ALLMedicine™ Alpha-1 Antitrypsin Deficiency Center

Research & Reviews  317 results

Characterization of hepatic inflammatory changes in a C57BL/6J mouse model of alpha-1 a...
https://doi.org/10.1152/ajpgi.00207.2022
American Journal of Physiology. Gastrointestinal and Live... Khodayari N, Oshins R et. al.

Oct 19th, 2022 - Alpha-1 antitrypsin deficiency (AATD) is a genetic disease caused by hepatic accumulation of mutant alpha-1 antitrypsin (ZAAT). Here, we sought to characterize the liver pathophysiology of a human transgenic mouse model for AATD with a manifestati...

Unique and shared systemic biomarkers for emphysema in Alpha-1 Antitrypsin deficiency a...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9507992
EBioMedicine Serban KA, Pratte KA et. al.

Sep 27th, 2022 - Alpha-1 Antitrypsin (AAT) deficiency (AATD), the most common genetic cause of emphysema presents with unexplained phenotypic heterogeneity in affected subjects. Our objectives to identify unique and shared AATD plasma biomarkers with chronic obstr...

Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency
https://clinicaltrials.gov/ct2/show/NCT03815396

Sep 13th, 2022 - This is an open-label, 2-part, dose-escalating, Phase 1 study of INBRX-101 (rhAAT-Fc). Part 1 will consist of single ascending dose (SAD) administration of INBRX-101 and Part 2 will consist of multiple ascending dose (MAD) administrations of INBRX...

COPD inhaler therapy: A path to success
https://www.mdedge.com/familymedicine/article/257727/pulmonology/copd-inhaler-therapy-path-success
MDedge Family Medicine; Michael Arnold, DO, FAAFP, Cate Vordtriede, PharmD, BCPS et. al.

Sep 12th, 2022 - Managing chronic obstructive pulmonary disease (COPD) presents a significant challenge to busy clinicians in many ways, especially when one is approaching the long list of inhaled pharmaceutical agents with an eye toward a cost-effective, patient-.

Serum biomarkers correlated with liver stiffness assessed in a multicenter study of ped...
https://doi.org/10.1002/hep.32777
Hepatology (Baltimore, Md.); Leung DH, Devaraj S et. al.

Sep 8th, 2022 - Detailed investigation of the biological pathways leading to hepatic fibrosis and identification of liver fibrosis biomarkers may facilitate early interventions for pediatric cholestasis. A targeted enzyme-linked immunosorbent assay-based panel of...

see more →

Guidelines  3 results

Non-invasive diagnosis and follow-up of rare genetic liver diseases.
https://doi.org/10.1016/j.clinre.2021.101768
Clinics and Research in Hepatology and Gastroenterology; Sobesky R, Guillaud O et. al.

Aug 1st, 2021 - Rare genetic liver diseases can result in multi-systemic damage, which may compromise the patient's prognosis. Wilson's disease and alpha-1 antitrypsin deficiency must be investigated in any patient with unexplained liver disease. Cystic fibrosis ...

ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries.
https://doi.org/10.1038/ajg.2016.517
The American Journal of Gastroenterology; Kwo PY, Cohen SM et. al.

Dec 21st, 2016 - Clinicians are required to assess abnormal liver chemistries on a daily basis. The most common liver chemistries ordered are serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and bilirubin. These tests sh...

Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: a Canadian Th...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3373286
Canadian Respiratory Journal; Marciniuk DD, Hernandez P et. al.

Apr 27th, 2012 - Alpha-1 antitrypsin (A1AT) functions primarily to inhibit neutrophil elastase, and deficiency predisposes individuals to the development of chronic obstructive pulmonary disease (COPD). Severe A1AT deficiency occurs in one in 5000 to one in 5500 o...

see more →

Clinicaltrials.gov  34 results

Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency
https://clinicaltrials.gov/ct2/show/NCT03815396

Sep 13th, 2022 - This is an open-label, 2-part, dose-escalating, Phase 1 study of INBRX-101 (rhAAT-Fc). Part 1 will consist of single ascending dose (SAD) administration of INBRX-101 and Part 2 will consist of multiple ascending dose (MAD) administrations of INBRX...

Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency
https://clinicaltrials.gov/ct2/show/NCT03679598

Aug 25th, 2022 - Alpha-1 antitrypsin deficiency (AATD) is the most common genetic cause of chronic obstructive pulmonary disease (COPD) and early-onset emphysema. AATD is characterized by low AAT levels; leading to excessive neutrophil elastase (NE) mediated lung ...

Respreeza® Self-administration and Learning Program (AmAREtTI Study)
https://clinicaltrials.gov/ct2/show/NCT04262284

Aug 2nd, 2022 - According to the Respreeza® Summary of Product Characteristics, the initial infusions must be administered under the supervision of a health professional experienced in the treatment of alpha-1 antitrypsin deficiency, although subsequent infusions...

Optimization of Donor-Recipient Matching in Lung Transplantation
https://clinicaltrials.gov/ct2/show/NCT05195853

Jun 30th, 2022 - Lung transplantation is the curative treatment for end-stage respiratory failure involving highly selected patients. In 2018, the International Transplant Registry counts 69200 lung transplants among 260 transplant centers. Between 2010 and June 2...

An Extension Study of Belcesiran in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATLD)
https://clinicaltrials.gov/ct2/show/NCT05146882

Jun 27th, 2022 - This is a Phase 2, multicenter, open-label extension of Study DCR-A1AT-201, designed to evaluate the long-term safety and further characterize the pharmacodynamics (PD) of belcesiran in adult patients with PiZZ AATLD.

see more →

News  47 results

COPD inhaler therapy: A path to success
https://www.mdedge.com/familymedicine/article/257727/pulmonology/copd-inhaler-therapy-path-success
MDedge Family Medicine; Michael Arnold, DO, FAAFP, Cate Vordtriede, PharmD, BCPS et. al.

Sep 12th, 2022 - Managing chronic obstructive pulmonary disease (COPD) presents a significant challenge to busy clinicians in many ways, especially when one is approaching the long list of inhaled pharmaceutical agents with an eye toward a cost-effective, patient-.

COPD Screening for Asymptomatic Adults? USPSTF Weighs In, Again
https://www.medscape.com/viewarticle/973787

May 11th, 2022 - Screening for chronic obstructive pulmonary disease (COPD) in asymptomatic adults has no net benefit, according to a U.S. Preventive Services Task Force (USPSTF) reassessment of its 2016 screening recommendations. The new recommendation is in line...

COPD screening for asymptomatic adults? USPSTF weighs in, again
https://www.mdedge.com/chestphysician/article/254452/copd/copd-screening-asymptomatic-adults-uspstf-weighs-again
Mark S. Lesney, PhD, MDedge News

May 10th, 2022 - Screening for chronic obstructive pulmonary disease (COPD) in asymptomatic adults has no net benefit, according to a U. S.

Deja Vu All Over Again; Delay of Game: NFL Vaccine Pushback; Third FDA Advisor Quits
https://www.medpagetoday.com/infectiousdisease/covid19/93049

Jun 11th, 2021 - Note that some links may require registration or subscription. Here we go again. As cruise lines struggle to recover from COVID-19, two passengers aboard a Royal Caribbean ship tested positive for coronavirus; all crew and passengers over 16 were ...

HCC Etiologic Risk Factors and Global Prevalence
https://www.onclive.com/view/hcc-etiologic-risk-factors-and-global-prevalence

Apr 2nd, 2021 - Minsig Choi, MD: What are the etiology risk factors in the development of hepatocellular cancer? We all know that hepatocellular cancer or liver cancer is caused by a chronic irritation or inflammations. Usually the most common causes of this irri...

see more →

Patient Education  10 results see all →